Company: REVB
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0000950170-25-066897
Chunk: 1

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 2
Chunk 1
---
 to obtain financing on acceptable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of our stockholders. If we are unable to obtain funding we could be required to delay, reduce or eliminate research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect our business operations.

We have incurred recurring losses since our inception, including a net loss of $2.1 million for the three months ended March 31, 2025 and $2.7 million for the three months ended March 31, 2024. As of March 31, 2025 we had an accumulated deficit of $42.6 million. We expect to continue to generate operating losses and negative operating cash flows for the foreseeable future if and as we:

• continue the research and development of our product candidates;

• initiate clinical studies for, or preclinical development of, our product candidates;

• further develop and refine the manufacturing processes of our product candidates;

• change or add manufacturers or suppliers of product candidate materials;

• seek regulatory and marketing authorizations for any of our product candidates that successfully complete development;

• acquire or license other product candidates, technologies or biological materials;

• make milestone, royalty or other payments under future license agreements;

• obtain, maintain, protect and enforce our intellectual property portfolio;

• seek to attract and retain new and existing skilled personnel;

• create additional infrastructure to support our operations as a public company and incur increased legal, accounting, investor relations and other expenses; and

• experience delays or encounter issues with any of the above.

Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of our clinical studies and our expenditures on other research and development activities.

We have never generated revenue and do not expect to generate revenue from product sales unless and until we successfully complete development and obtain regulatory approval for Product Candidates or other product candidates, which we expect will not be for at least several years, if ever. Accordingly, until such time as we can generate significant revenue from sales of Product Candidates or other product candidates, if ever, we expect to finance our cash needs through a combination of public or private equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. Our failure to raise capital or enter into such other arrangements when needed would have a negative impact on our financial condition and could